| scholarly article | Q13442814 |
| P50 | author | Bart Barlogie | Q66380853 |
| Andrzej Jakubowiak | Q89987696 | ||
| Brian Durie | Q104629750 | ||
| P2093 | author name string | Jeffrey A Zonder | |
| Mohamad A Hussein | |||
| John J Crowley | |||
| Vanessa Bolejack | |||
| P2860 | cites work | Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. | Q33498422 |
| Estimation of failure probabilities in the presence of competing risks: new representations of old estimators | Q33594562 | ||
| Evaluation of survival data and two new rank order statistics arising in its consideration | Q34054360 | ||
| International staging system for multiple myeloma | Q34408882 | ||
| Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 | ||
| Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. | Q36848183 | ||
| Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities | Q36941047 | ||
| Role of autologous stem-cell transplantation in multiple myeloma | Q37028583 | ||
| Single versus double autologous stem-cell transplantation for multiple myeloma. | Q44706045 | ||
| Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial | Q46745193 | ||
| Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group | Q46859424 | ||
| Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. | Q46907944 | ||
| Thalidomide and hematopoietic-cell transplantation for multiple myeloma | Q46981475 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| Maintenance therapy with thalidomide improves survival in patients with multiple myeloma | Q80011690 | ||
| One or two autografts for myeloma? | Q80942743 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple myeloma | Q467635 |
| thalidomide | Q203174 | ||
| autotransplantation | Q379071 | ||
| dexamethasone | Q422252 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 3510-3517 | |
| P577 | publication date | 2009-06-22 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). | |
| P478 | volume | 27 |
| Q44885909 | Continuous infusion cyclophosphamide and low-dose total body irradiation is a safe and effective conditioning regimen for autologous transplant in multiple myeloma |
| Q45285966 | Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma |
| Q56982314 | Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma |
| Q37835695 | Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement |
| Q56986459 | The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF |
| Q36612613 | The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development |
| Q38677358 | The role of tandem stem cell transplantation for multiple myeloma patients |
| Q97645319 | Unrealized potential of drug repositioning in europe during COVID-19 and beyond: a physcian's perspective |
Search more.